[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vascular-surgical-procedure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vascular-surgical-procedure":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,56,86,116],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":35,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100431190","phase-4-opioid-free-anesthesia-analgesia-strategy-and-surgical-stress-in-elective-open-abdominal-aortic-aneurysm-repair-100431190",false,"NCT04894864","Opioid Free Anesthesia-Analgesia Strategy and Surgical Stress in Elective Open Abdominal Aortic Aneurysm Repair","Effect of a Perioperative Opioid Free Anesthesia-Analgesia (OFA-A) Strategy on Surgical Stress Response in Elective Open Abdominal Aortic Aneurysm Repair: A Prospective Randomized Study","Inclusion Criteria:\n\n1. Patient Consent\n2. Age between 40 and 85 years old\n3. Patients undergoing Elective Open Abdominal Aortic Infrarenal Aneurysm Repair\n\nExclusion Criteria:\n\n1. Immunocompromised patients\n2. Patients with active infection\n3. Reoperation on the aorta\n4. Inflammatory bowel Disease\n5. Malignancy\n6. Chronic Inflammatory conditions (e.g. Rheymatoid arthritis, Psoriatic arthritis)\n7. Chronic corticosteroid or immunosuppressive drug use\n8. Intraoperative transfusion with \\>2 units of packed Red Blood Cells","ALL","40 Years","85 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Open Abdominal Aortic Aneurysm (AAA) repair is a high-risk surgical procedure accompanied by intense endocrine and metabolic responses to surgical stress, with subsequent activation of the inflammatory cascade, cytokine and acute-phase protein release, and bone marrow activation. There is a proven correlation of surgical stress, which patients undergoing open AAA repair are subjected to, with patient outcome, morbidity\u002Fmortality, intensive care unit stay and overall length of stay. Modern general anesthetic techniques have been revised and rely on perioperative multimodal anesthetic and analgesic strategies for improved overall patient outcome. Based on this context of a multimodal anesthetic technique and having taken into consideration the international \"opioid-crisis\" epidemic, an Opioid Free Anesthesia-Analgesia (OFA-A) strategy started to emerge. It is based on the administration of a variety of anesthetic\u002Fanalgesic agents with different mechanisms of action, including immunomodulating and anti-inflammatory effects.\n\nOur basic hypothesis is that the implementation of a perioperative multimodal OFA-A strategy, involving the administration of pregabalin, ketamine, dexmedetomidine, lidocaine, dexamethasone, dexketoprofen, paracetamol and magnesium sulphate, will lead to attenuation of surgical stress response compared to a conventional Opioid-Based Anesthesia-Analgesia (OBA-A) strategy. Furthermore, the anticipated attenuation of the inflammatory response, is pressumed to be associated with equal or improved analgesia, compared to a perioperative OBA-A technique.",[27,28,29,30,31,32,33,34],"Elective Surgical Procedures","Postoperative Pain","Anesthesia","Opioid Use","Abdominal Aortic Aneurysm Without Rupture","Vascular Surgical Procedure","Interleukin 6","Immunomodulators",[36,37,38,39,40,41,42],"Opioid-free Anesthesia-Analgesia","Cytokines","Opioid-based Anesthesia-Analgesia","Haemodynamic Stability","Open Abdominal Aortic Aneurysm Repair","Immunomodulation","Inflammatory Markers","RECRUITING","2026-06-13",{"date":46,"type":47},"2026-06-16","ACTUAL",{"date":49,"type":47},"2020-10-08",{"date":51,"type":21},"2027-09-01",{"name":53,"class":54},"University of Crete","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":16,"minAge":64,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":68,"conditions":69,"keywords":70,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":55},"100363625","measurement-of-nt-probnp-to-predict-outcomes-in-surgery-100363625","NCT04014647","Measurement Of NT-proBNP to Predict Outcomes in Surgery","Peri-operative Measurement of NT-proBNP to Predict Outcomes in Patients Undergoing Elective Vascular Surgery","MOBOS","Inclusion Criteria:\n\n* Patients who are equal to or over 18 years old\n* Patients scheduled to undergo elective surgery for the following procedures:\n* Infrainguinal arterial reconstruction\n* Aortic aneurysm\n* Aorto-bifemoral bypass \u002F or aortic endarterectomy\n* Femoro-popliteal bypass\n* Femoro-distal bypass\n* Femoral endarterectomy\n* Femoro-femoral crossover\n* Axillo-femoral bypass\n* Elective carotid surgery\n* Patients having either general or regional anaesthesia for their surgery\n\nExclusion Criteria:-\n\n* Patients undergoing emergency surgery\n* Those who are unable or unwilling to give informed consent\n* Patients with unstable coronary syndromes (acute or recent MI with evidence of important ischemic risk by clinical symptoms or stress testing or unstable or severe angina pectoris)\n* Patients with decompensated heart failure (new onset shortness of breath and rales together with echocardiographic evidence of cardiac dysfunction or deterioration of chronic heart failure despite heart failure therapy)\n* Patients with chronic atrial fibrillation","18 Years",{"count":66,"type":21},200,"OBSERVATIONAL","The team is investigating whether N-terminal pro B-type natriuretic peptide (NT-proBNP) and other cardiac markers are useful for predicting outcomes for patients undergoing vascular surgery. By measuring NT-proBNP before and after surgery, the investigators may be able to determine which patients are at risk of an adverse outcome, such as a heart attack or death.",[32],[32,71,72,73,74,75,76],"Pro-brain natriuretic peptide (1-76)","Natriuretic Peptide, Brain","Troponin I","Galectin 3","Biomarkers","Risk","2026-06-05",{"date":79,"type":47},"2026-06-08",{"date":81,"type":47},"2019-09-05",{"date":83,"type":21},"2029-09-05",{"name":85,"class":54},"Norfolk and Norwich University Hospitals NHS Foundation Trust",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":64,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":22,"phases":97,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":55},"100631325","lymphatic-injury-visualization-in-vascular-surgery-100631325","NCT07499206","Lymphatic Injury Visualization in Vascular Surgery","Visualization and Treatment of Lymphatic Injury During Vascular Surgery Procedures in the Groin: A Pilot Study","LymphFistula-P","Inclusion Criteria:\n\n* adult patients undergoing vascular surgery procedures in the groin\n* signed informed consent for study participation\n\nExclusion Criteria:\n\n* pregnant or lactating women\n* prior groin surgery\n* infected surgical site in the groin\n* necessity for further incisions (e.g. bypass surgery)\n* incapability of judgement or consent","100 Years",{"count":96,"type":21},60,[98],"NA","This study aims to assess a simple intervention: Visualization of lymphatic injury + treatment (in case of detection). This will generate data on the incidence of intraoperative lymphatic injury and the effect of treatment. This data will then hopefully enable a multi-center RCT to generate high level evidence on this matter.",[32,101,102,103,104,105],"Peripheral Arterial Disease(PAD)","Acute Ischemia","Hemmorhage","Aneurysm","Pseudoaneurysm","NOT_YET_RECRUITING","2026-03-23",{"date":109,"type":47},"2026-03-30",{"date":111,"type":21},"2026-04",{"date":113,"type":21},"2027-04",{"name":115,"class":54},"University Hospital, Basel, Switzerland",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":64,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":126,"conditions":127,"keywords":131,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":151,"leadSponsor":153,"locationsCount":156},"100605555","leica-microsystems-sponsored-study-to-collect-and-confirm-clinical-data-on-the-performance-of-the-glow800-device-when-used-in-accordance-with-its-intended-use-100605555","NCT07164040","Leica Microsystems Sponsored Study to Collect and Confirm Clinical Data on the Performance of the GLOW800 Device When Used in Accordance With Its Intended Use.","Fluorescence Visualization and Image Quality Evaluation of Digital Visualization During Standard of Care Procedure in the Cerebral Vascular Area as Well as Blood Flow During Plastic and Reconstructive Surgery (PRS) (Leica GLOW800)","IMED-GLOW800","Inclusion Criteria:\n\nCandidates for the study must be appropriate patients for surgical interventions in the cerebral vascular area or for plastic and reconstructive surgery and have to fulfil all of the following inclusion criteria to be eligible for the recruitment of the study.\n\n1. Participants must be 18 years of age or older at the time of signing the informed consent.\n2. Participants must have a condition requiring surgical intervention in the cerebral vascular area as well as during plastic and reconstructive surgery.\n3. The Indocyanine Green (ICG) cyanine dye is administered as a contrast agent per instructions for use.\n4. The participant or their legal representative must understand the study and have voluntarily signed and dated the Informed Consent Form, which has been approved by the Sponsor and the Ethics Committee for this study\n\nExclusion Criteria:\n\nCandidates who meet any of the following exclusion criteria will not be eligible for recruitment in the study.\n\n1. Known allergy to Indocyanine Green (ICG) cyanine dye.\n2. Any uncontrolled systemic condition that may adversely affect the surgical outcome.\n3. Patients holding United States citizenship.\n4. Severe iodine-induced reactions to macromolecular iodine-containing compounds (e.g., iodinated contrast media, iodine-based antiseptics, or drugs like amiodarone), especially if the reaction involved anaphylaxis or respiratory compromise.",{"count":125,"type":21},29,"This post-market clinical follow-up (PMCF) study aims to confirm the safety and performance of the GLOW800 surgical microscope accessory when used in conjunction with the ARveo8x surgical microscope. The study evaluates fluorescence visualization and image quality during standard surgical procedures in the cerebral vascular area and plastic and reconstructive surgery. It is a non-interventional, observational study conducted in routine care settings across multiple European sites.",[128,129,32,130],"Reconstructive Surgical Procedures","Plastic Surgery","Cerebrovascular Disorder",[132,133,134,135,136,137,138,139,140,141,142,143,144,145,146],"GLOW800","Indocyanine-green (ICG)","Near Infrared","plastic and reconstructive surgery","ARveo8X","Surgical Microscope","Fluorescence imaging","Cerebrovascular surgery","Intraoperative visualization","Post-market clinical follow-up (PMCF)","Image quality assessment","3D visualization","Heads-up surgery","Vascular imaging","Digital surgical workflow","2026-01-16",{"date":149,"type":47},"2026-01-20",{"date":149,"type":21},{"date":152,"type":21},"2027-07-30",{"name":154,"class":155},"Leica Microsystems (Schweiz) AG","INDUSTRY",3]